Equity Overview
Price & Market Data
Price: $1.72
Daily Change: +$0.09 / 5.23%
Daily Range: $1.60 - $1.72
Market Cap: $129,473,555
Daily Volume: 339,968
Performance Metrics
1 Week: 9.62%
1 Month: 23.91%
3 Months: 42.50%
6 Months: 71.00%
1 Year: 83.87%
YTD: 33.59%
Company Details
Employees: 131
Sector: Health technology
Industry: Biotechnology
Country:
Details
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.